Dose-dependent fecal bile acid excretion with apical sodium-dependent bile acid transporter inhibitors maralixibat and volixibat in a doseranging phase 1 study in overweight and obese adults

Authors
Category Primary study
JournalHepatology v70 suppl.1 2019
Year 2019
This article has no abstract
Epistemonikos ID: 8ce7bdf6d56c787e69dead313ec505f63aaae0f6
First added on: Feb 11, 2025